NASDAQ:CRVS Corvus Pharmaceuticals - CRVS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.68 0.00 (0.00%) (As of 03/21/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.69▼$0.7150-Day Range$0.65▼$0.9152-Week Range$0.61▼$2.11Volume22,737 shsAverage Volume99,210 shsMarket Capitalization$31.89 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Corvus Pharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside338.0% Upside$3.00 Price TargetShort InterestHealthy0.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment-0.34Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.92) to ($0.69) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.22 out of 5 starsMedical Sector321st out of 983 stocksPharmaceutical Preparations Industry143rd out of 478 stocks 3.5 Analyst's Opinion Consensus RatingCorvus Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.00, Corvus Pharmaceuticals has a forecasted upside of 338.0% from its current price of $0.69.Amount of Analyst CoverageCorvus Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.50% of the float of Corvus Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCorvus Pharmaceuticals has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Corvus Pharmaceuticals has recently increased by 35.87%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldCorvus Pharmaceuticals does not currently pay a dividend.Dividend GrowthCorvus Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CRVS. Previous Next 1.5 News and Social Media Coverage News SentimentCorvus Pharmaceuticals has a news sentiment score of -0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Corvus Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 9 people have searched for CRVS on MarketBeat in the last 30 days. This is a decrease of -68% compared to the previous 30 days.MarketBeat Follows1 people have added Corvus Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Corvus Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders29.70% of the stock of Corvus Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.45% of the stock of Corvus Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Corvus Pharmaceuticals are expected to grow in the coming year, from ($0.92) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Corvus Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Corvus Pharmaceuticals is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCorvus Pharmaceuticals has a P/B Ratio of 0.33. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Corvus Pharmaceuticals (NASDAQ:CRVS) StockCorvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, and Joseph J. Buggy on January 27, 2014 and is headquartered in Burlingame, CA.Read More Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Stock News HeadlinesMarch 21, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2022 Financial Results on March 28, 2023March 20, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Corvus Pharmaceuticals (NASDAQ:CRVS)March 21, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 14, 2023 | finance.yahoo.comCorvus Pharmaceuticals to Present New CPI-818 Data Demonstrating the Potential of ITK Inhibition as a Treatment for Solid Tumors at the American Association for Cancer Research (AACR) Annual MeetingMarch 13, 2023 | americanbankingnews.comCorvus Pharmaceuticals (NASDAQ:CRVS) Earns Sell Rating from Analysts at StockNews.comFebruary 21, 2023 | finance.yahoo.comCorvus Pharma's HIV Candidate Shows Potential To Prevent Virus Re-EmergenceFebruary 21, 2023 | finance.yahoo.comCorvus Pharmaceuticals Announces New Data Demonstrating CPI-818’s (ITK Inhibitor) Potential to Block HIV Latency ReversalFebruary 21, 2023 | finance.yahoo.com'Block-and-lock' HIV path targeted by UCSF professor, Peninsula drug companyMarch 21, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 2, 2023 | finance.yahoo.comQuite a few insiders invested in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) last year which is positive news for shareholdersJanuary 20, 2023 | forbes.comCorvus PharmaceuticalsJanuary 13, 2023 | reuters.comCRVS.A - | Stock Price & Latest News | ReutersDecember 12, 2022 | finance.yahoo.comCorvus Pharmaceuticals Presents Updated Data from CPI-818 (ITK Inhibitor) Phase 1/1b Clinical Trial at the 64th American Society of Hematology (ASH) Annual Meeting & ExpositionDecember 5, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Host Investor Conference Call and Webcast on December 12, 2022November 14, 2022 | finance.yahoo.comJames Rosenbaum Presented the Distinguished Service Award by the American College of RheumatologyNovember 4, 2022 | apnews.comCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 4, 2022 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 4, 2022 | finance.yahoo.comCorvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial ResultsNovember 3, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Present Updated CPI-818 (ITK Inhibitor) Data at the 64th American Society of Hematology (ASH) Annual Meeting & ExpositionNovember 2, 2022 | msn.comEarnings Preview For Corvus PharmaceuticalsOctober 27, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2022 Financial Results on November 3, 2022October 25, 2022 | finance.yahoo.comCorvus Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Trial of Ciforadenant as Potential First Line Treatment for Patients with Renal Cell CancerSeptember 27, 2022 | finance.yahoo.comCorvus Pharma's Partner Secures China Approval For Early-Stage Mupadolimab Trial For Lung, Head & Neck CancerSeptember 26, 2022 | finance.yahoo.comCorvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in ChinaSeptember 15, 2022 | nasdaq.comA number of insiders bought Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) stock last year, which is great news for shareholdersSeptember 6, 2022 | finance.yahoo.comCorvus Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 26, 2022 | finance.yahoo.comGreat news for Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS): Insiders acquired stock in large numbers last yearSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CRVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Corvus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CRVS Company Calendar Last Earnings10/31/2021Today3/21/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CRVS CUSIPN/A CIK1626971 Webwww.corvuspharma.com Phone(650) 900-4520FaxN/AEmployees28Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+338.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-43,240,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-49.08% Return on Assets-42.46% Debt Debt-to-Equity RatioN/A Current Ratio3.67 Quick Ratio3.67 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.09 per share Price / Book0.33Miscellaneous Outstanding Shares46,550,000Free Float32,727,000Market Cap$31.89 million OptionableNot Optionable Beta1.04 Key ExecutivesRichard A. MillerChairman, President & Chief Executive OfficerLeiv LeaChief Financial OfficerGabriel LucianoVice President-Clinical OperationsSuresh MahabhashyamVice President-Clinical DevelopmentJames RosenbaumSenior Vice President-ResearchKey CompetitorsVistaGen TherapeuticsNASDAQ:VTGNAcer TherapeuticsNASDAQ:ACERMEI PharmaNASDAQ:MEIPUnicycive TherapeuticsNASDAQ:UNCYKala PharmaceuticalsNASDAQ:KALAView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 365,796 shares on 2/15/2023Ownership: 4.080%Morgan StanleyBought 33,288 shares on 2/15/2023Ownership: 0.156%Discovery Capital Management LLC CTBought 548,727 shares on 2/14/2023Ownership: 1.179%Two Sigma Investments LPSold 148,521 shares on 2/14/2023Ownership: 0.604%Renaissance Technologies LLCSold 326,887 shares on 2/13/2023Ownership: 1.393%View All Insider TransactionsView All Institutional Transactions CRVS Stock - Frequently Asked Questions Should I buy or sell Corvus Pharmaceuticals stock right now? 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corvus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRVS shares. View CRVS analyst ratings or view top-rated stocks. What is Corvus Pharmaceuticals' stock price forecast for 2023? 2 Wall Street analysts have issued 12 month price targets for Corvus Pharmaceuticals' stock. Their CRVS share price forecasts range from $2.00 to $4.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 338.0% from the stock's current price. View analysts price targets for CRVS or view top-rated stocks among Wall Street analysts. How have CRVS shares performed in 2023? Corvus Pharmaceuticals' stock was trading at $0.85 on January 1st, 2023. Since then, CRVS shares have decreased by 19.4% and is now trading at $0.6850. View the best growth stocks for 2023 here. Are investors shorting Corvus Pharmaceuticals? Corvus Pharmaceuticals saw a increase in short interest in the month of February. As of February 28th, there was short interest totaling 171,200 shares, an increase of 35.9% from the February 13th total of 126,000 shares. Based on an average trading volume of 122,500 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.5% of the shares of the company are short sold. View Corvus Pharmaceuticals' Short Interest. When is Corvus Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our CRVS earnings forecast. How were Corvus Pharmaceuticals' earnings last quarter? Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) released its earnings results on Sunday, October, 31st. The company reported ($0.24) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.24). What is Richard A. Miller, MD's approval rating as Corvus Pharmaceuticals' CEO? 4 employees have rated Corvus Pharmaceuticals Chief Executive Officer Richard A. Miller, MD on Glassdoor.com. Richard A. Miller, MD has an approval rating of 100% among the company's employees. This puts Richard A. Miller, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 73.0% of employees surveyed would recommend working at Corvus Pharmaceuticals to a friend. What other stocks do shareholders of Corvus Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Corvus Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Dynavax Technologies (DVAX), Vaxart (VXRT), Zosano Pharma (ZSAN), SCYNEXIS (SCYX), Miragen Therapeutics (MGEN), Aldeyra Therapeutics (ALDX) and Bionano Genomics (BNGO). When did Corvus Pharmaceuticals IPO? (CRVS) raised $75 million in an initial public offering (IPO) on Wednesday, March 23rd 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Credit Suisse and Cowen and Company acted as the underwriters for the IPO and Guggenheim Securities, Cantor Fitzgerald and BTIG were co-managers. What is Corvus Pharmaceuticals' stock symbol? Corvus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRVS." Who are Corvus Pharmaceuticals' major shareholders? Corvus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (4.08%), Renaissance Technologies LLC (1.39%), Discovery Capital Management LLC CT (1.18%), Two Sigma Investments LP (0.60%), Morgan Stanley (0.16%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Ecor1 Capital, Llc, Holdings A/S Novo, Leiv Lea, Orbimed Advisors Llc, Richard A Md Miller and William Benton Jones. View institutional ownership trends. How do I buy shares of Corvus Pharmaceuticals? Shares of CRVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Corvus Pharmaceuticals' stock price today? One share of CRVS stock can currently be purchased for approximately $0.69. How much money does Corvus Pharmaceuticals make? Corvus Pharmaceuticals (NASDAQ:CRVS) has a market capitalization of $31.89 million. The company earns $-43,240,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. How can I contact Corvus Pharmaceuticals? Corvus Pharmaceuticals' mailing address is 863 Mitten Road Suite102, BURLINGAME CA, 94010. The official website for the company is www.corvuspharma.com. The company can be reached via phone at (650) 900-4520 or via email at llea@corvuspharma.com. This page (NASDAQ:CRVS) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.